Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | CASP3 | P42574 | 1/20 | 0.62 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.62 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.62 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3584951 | 0.98 | POLB (0.64) | POLBL3MBTL1LMNACYP2C19CYP1A2 | |
| SCHEMBL28348218 | 0.90 | TSHR (0.60) | POLBL3MBTL1LMNACYP2C19CYP1A2 | |
| SCHEMBL5532922 | 0.86 | POLB (0.51) | POLBL3MBTL1LMNACYP2C19CYP1A2 | |
| Niacin SCHEMBL6418540 | 0.85 | CYP2C9 (0.58) | POLBL3MBTL1LMNACYP2C19CYP1A2 | |
| SCHEMBL30609724 | 0.84 | L3MBTL1 (0.64) | POLBL3MBTL1LMNACYP2C19CYP1A2 | |
| SCHEMBL28350930 | 0.84 | TP53 (0.63) | POLBL3MBTL1LMNAKMT2AMEN1 | |
| SCHEMBL28351060 | 0.83 | POLB (0.58) | POLBL3MBTL1LMNACYP2C19CYP1A2 | |
| SCHEMBL109206 | 0.83 | TSHR (0.63) | L3MBTL1CYP1A2TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL29571304 | 0.83 | TSHR (0.63) | L3MBTL1CYP1A2TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL7954798 | 0.83 | ALDH1A1 (0.63) | POLBL3MBTL1LMNACYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 779 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035768-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2018-07-31 | — | — | US | claimed |
| US-20180179160-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-06-28 | — | — | US | claimed |
| EP-3078658-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2016-10-12 | — | — | EP | claimed |
| US-5248781-A | Preparation of substituted anilino-nicotinic acid derivatives | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1993-09-28 | — | — | US | claimed |
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260132127-A1 | NOVEL SPIRO COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-05-14 | — | — | US | disclosed |
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2026-05-07 | — | — | US | disclosed |
| CN-121779321-A | Industrial production method of 2-chloronicotinic acid | 江苏三鹏生物化工有限公司 | 2026-04-03 | — | — | CN | disclosed |
| CN-120790068-A | Continuous production device and production method for 2-chloronicotinic acid | 苏利(宁夏)新材料科技有限公司 | 2025-10-17 | — | — | CN | disclosed |
| US-20250236897-A1 | PROCESSES FOR PREPARATION OF AVACOPAN AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2025-07-24 | — | — | US | disclosed |
| US-20250213547-A1 | METHODS OF TREATING NEUROLOGICAL DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2025-07-03 | — | — | US | disclosed |
| CN-115710217-B | Flunixin meglumine synthesis method suitable for industrial production | 江苏恒盛药业有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-4740511-A | ANTIALLERGENS, ANTIINFLAMMATORY, ANTIULCER AGENTS | SCHERING CORPORATION (US) | 1988-04-26 | — | — | US | disclosed |
| US-4680298-A | Tricyclic anti-allergy and use as anti-inflammatory agents | SCHERING CORPORATION (US) | 1987-07-14 | — | — | US | disclosed |
| US-4632923-A | Substituted hetero spiro pyridine derivatives as anti-allergy and anti-inflammatory agents | SCHERING CORPORATION (US) | 1986-12-30 | — | — | US | disclosed |
| CN-85106252-A | The preparation method of compound and application thereof | — | 1986-06-10 | — | — | CN | disclosed |
| EP-0174717-A1 | Benzimidazoles, and their production formulation and use as gastric acid secretion inhibitors | FISONS plc (GB) | 1986-03-19 | — | — | EP | disclosed |
| EP-0144996-A2 | Substituted spiro pyridine derivatives, pharmaceutical compositions containing them and processes for the preparation of such compounds and compositions | SCHERING CORPORATION (US) | 1985-06-19 | — | — | EP | disclosed |
| EP-0127135-A2 | Fused tricyclic derivatives of naphthyridinone and pyridone and the corresponding thiones | SCHERING CORPORATION (US) | 1984-12-05 | — | — | EP | disclosed |
| US-4205073-A | Anti-diarrheal anilino nicotinic acids and method of using same | SCHERING CORPORATION (US) | 1980-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236897-A1 | PROCESSES FOR PREPARATION OF AVACOPAN AND INTERMEDIATES THEREOF | DHPS, VARS1, AGPS | POLB 158/4885L3MBTL1 4637/4885LMNA 1946/4885 |
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | HTR6, HTR3C, OPRD1 | POLB 1831/4885L3MBTL1 783/4885LMNA 2257/4885 |
| US-20180179160-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | POLB 3658/4885L3MBTL1 2243/4885LMNA 2969/4885 |
| US-10035768-B2 | C5aR antagonists | C5AR1, C5AR2, C3AR1 | POLB 3658/4885L3MBTL1 2243/4885LMNA 2969/4885 |
| US-20250213547-A1 | METHODS OF TREATING NEUROLOGICAL DISEASES | SMN1; SMN2, PMP22, GBA2 | POLB 2602/4885L3MBTL1 2698/4885LMNA 2937/4885 |
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | BTK, CNKSR1, SYK | POLB 1177/4885L3MBTL1 384/4885LMNA 3447/4885 |
| US-20260132127-A1 | NOVEL SPIRO COMPOUND | TRHR, NR3C2, THRB | POLB 4761/4885L3MBTL1 3822/4885LMNA 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.